{"id":16404,"date":"2024-12-04T22:01:00","date_gmt":"2024-12-04T16:31:00","guid":{"rendered":"https:\/\/dev.sunpharma.com\/?page_id=16404"},"modified":"2024-12-09T08:59:43","modified_gmt":"2024-12-09T03:29:43","slug":"capital-evolution","status":"publish","type":"page","link":"https:\/\/dev.sunpharma.com\/he\/capital-evolution\/","title":{"rendered":"Capital Evolution"},"content":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” admin_label=”Popup – #undefined” _builder_version=”4.7.4″ background_image=”https:\/\/dev.sunpharma.com\/wp-content\/uploads\/2021\/03\/investor-banner.jpg” parallax=”on” saved_tabs=”all” collapsed=”off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on” da_disable_devices=”off|off|off”][et_pb_fullwidth_header title=”Capital Evolution” header_fullscreen=”on” button_one_url=”#visionvalues” button_two_url=”#codeofconduct” _builder_version=”4.7.4″ title_font=”|700|||||||” title_text_color=”#f7941e” title_font_size=”40px” title_line_height=”1.2em” content_font=”||||||||” content_text_color=”#000000″ content_line_height=”1.8em” subhead_font=”||||||||” subhead_text_color=”rgba(0,0,0,0.6)” subhead_font_size=”22px” subhead_line_height=”1.4em” background_color=”rgba(255,255,255,0.7)” custom_button_one=”on” button_one_text_size=”20px” button_one_text_color=”#ffffff” button_one_bg_color=”#f7941e” button_one_border_width=”0px” button_one_font=”|||on|||||” button_one_use_icon=”off” custom_button_two=”on” button_two_text_size=”20px” button_two_text_color=”rgba(0,0,0,0.7)” button_two_bg_color=”#ffffff” button_two_border_width=”0px” button_two_font=”|||on|||||” button_two_use_icon=”off” button_two_custom_margin=”||||false|false” button_two_custom_margin_tablet=”” button_two_custom_margin_phone=”|||1px|false|false” button_two_custom_margin_last_edited=”on|desktop” button_two_custom_padding=”||||false|false” background_layout=”light” width=”50%” width_tablet=”” width_phone=”100%” width_last_edited=”on|phone” animation_style=”fade” animation_duration=”500ms” animation_delay=”300ms” title_font_tablet=”” title_font_phone=”” title_font_last_edited=”on|phone” content_font_tablet=”” content_font_phone=”” content_font_last_edited=”on|phone”]At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.[\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.7.4″ _module_preset=”default” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on” da_disable_devices=”off|off|off”][et_pb_row _builder_version=”4.7.4″ width=”90%” max_width=”2560px” custom_padding=”0px||0px||true|false”][et_pb_column type=”4_4″ _builder_version=”4.4.2″][et_pb_text _builder_version=”4.7.4″ _module_preset=”default” header_font=”|700|||||||” header_text_color=”#f7941e” header_font_size=”25px” header_line_height=”1.2em” header_2_font=”|700|||||||” header_2_text_color=”#f7941e” header_2_font_size=”25px” header_2_line_height=”1.2em”]<\/p>\n

Capital Evolution<\/h1>\n

[\/et_pb_text][et_pb_code _builder_version=”4.7.4″ _module_preset=”default”]\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Date of Allotment<\/th>No. of equity shares issued<\/th>Face Value (Rs.)<\/th>Type of Issue<\/th>Cumulative capital
\n(No. of equity shares)<\/th>\n<\/tr>\n<\/thead>\n
01 March 1993<\/td>200,000<\/td>10.00<\/td>Conversion of Partnership Firm<\/td>200,000<\/td>\n<\/tr>\n
30 March 1993<\/td>700,000<\/td>10.00<\/td>Cash<\/td>900,000<\/td>\n<\/tr>\n
18 September 1993<\/td>5,100,000<\/td>10.00<\/td>Cash<\/td>6,000,000<\/td>\n<\/tr>\n
10 November 1993<\/td>1,000,000<\/td>10.00<\/td>Rights Issue<\/td>7,000,000<\/td>\n<\/tr>\n
08 January 1994<\/td>185,000<\/td>10.00<\/td>Cash<\/td>7,185,000<\/td>\n<\/tr>\n
01 June 1994<\/td>3,592,500<\/td>10.00<\/td>Bonus Issue
\n(in the ratio 1:2)<\/td>		10,777,500<\/td>\n<\/tr>\n
09 August 1994<\/td>323,400<\/td>10.00<\/td>Rights Issue<\/td>11,100,900<\/td>\n<\/tr>\n
08 December 1994<\/td>3,700,300<\/td>10.00<\/td>Public Issue<\/td>14,801,200<\/td>\n<\/tr>\n
07 February 1998<\/td>413,633<\/td>10.00<\/td>Allotment pursuant to amalgamation of Tamilnadu Dadha Pharmaceuticals Ltd.
\n(in the ratio of 1:4)<\/td>		15,214,833<\/td>\n<\/tr>\n
25 March 1999<\/td>208,000<\/td>10.00<\/td>Allotment pursuant to amalgamation of Milmet Laboratories Private Limited
\n(in the ratio of 4:5)<\/td>		15,422,833<\/td>\n<\/tr>\n
01 April 2000<\/td>30,844,466<\/td>10.00<\/td>Bonus Issue
\n(in the ratio 2:1)<\/td>		46,267,299<\/td>\n<\/tr>\n
06 June 2000<\/td>477,581<\/td>10.00<\/td>Allotment pursuant to amalgamation of Gujarat Lyka Organics Limited
\n(In the ratio of 1:21.33)<\/td>		46,744,880<\/td>\n<\/tr>\n
16 January 2001<\/td>11,438<\/td>10.00<\/td>Allotment pursuant to amalgamation of Sun Pharmaceutical Exports Limited
\n(in the ratio of 4:5)<\/td>		46,756,318<\/td>\n<\/tr>\n
16 January 2001<\/td>200<\/td>10.00<\/td>Bonus (kept in abeyance)<\/td>46,756,518<\/td>\n<\/tr>\n
22 March 2001<\/td>-500<\/td>10.00<\/td>Forfeited by the Board of Directors at their Board Meeting held on 22.03.2001<\/td>46,756,018<\/td>\n<\/tr>\n
30 March 2002<\/td>18,519<\/td>10.00<\/td>Allotment pursuant to amalgamation of Pradeep Drug Company Limited
\n(in the ratio of 1:500)<\/td>		46,774,537<\/td>\n<\/tr>\n
28 August 2002<\/td>19,771<\/td>10.00<\/td>Allotment pursuant to amalgamation of M. J. Pharmaceuticals Limited
\n(in the ratio of 1:210)<\/td>		46,794,308<\/td>\n<\/tr>\n
21 January 2003<\/td>93,588,616<\/td>5.00<\/td>Sub-division\/split of existing equity shares of Rs.10 each into two equity shares of Rs.5 each<\/td>93,588,616<\/td>\n<\/tr>\n
15 March 2003<\/td>-209,000<\/td>5.00<\/td>Shares bought back destroyed<\/td>93,379,616<\/td>\n<\/tr>\n
28 March 2003<\/td>-156,838<\/td>5.00<\/td>Shares bought back destroyed<\/td>93,222,778<\/td>\n<\/tr>\n
16 April 2003<\/td>-174,300<\/td>5.00<\/td>Shares bought back destroyed<\/td>93,048,478<\/td>\n<\/tr>\n
08 May 2003<\/td>-262,732<\/td>5.00<\/td>Shares bought back destroyed<\/td>92,785,746<\/td>\n<\/tr>\n
23 May 2003<\/td>-30,068<\/td>5.00<\/td>Shares bought back destroyed<\/td>92,755,678<\/td>\n<\/tr>\n
08 June 2004<\/td>92,755,678<\/td>5.00<\/td>Bonus Issue
\n(in the ratio 1:1) <\/td>		185,511,356<\/td>\n<\/tr>\n
18 August 2005<\/td>4,274<\/td>5.00<\/td>Allotment pursuant to amalgamation of Phlox Pharmaceuticals Limited
\n(in the ratio of 1:790)<\/td>		185,515,630<\/td>\n<\/tr>\n
31 March 2006<\/td>216,007<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>185,731,637<\/td>\n<\/tr>\n
22 April 2006<\/td>154,291<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>185,885,928<\/td>\n<\/tr>\n
16 May 2006<\/td>61,716<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>185,947,644<\/td>\n<\/tr>\n
07 June 2006<\/td>58,445<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>186,006,089<\/td>\n<\/tr>\n
14 June 2006<\/td>61,716<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>186,067,805<\/td>\n<\/tr>\n
04 September 2006<\/td>30,858<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>186,098,663<\/td>\n<\/tr>\n
13 September 2006<\/td>98,746<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>186,197,409<\/td>\n<\/tr>\n
16 September 2006<\/td>462,875<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>186,660,284<\/td>\n<\/tr>\n
09 October 2006<\/td>306,668<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>186,966,952<\/td>\n<\/tr>\n
11 October 2006<\/td>61,716<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>187,028,668<\/td>\n<\/tr>\n
06 November 2006<\/td>262,293<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>187,290,961<\/td>\n<\/tr>\n
18 November 2006<\/td>50,916<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>187,341,877<\/td>\n<\/tr>\n
20 November 2006<\/td>462,875<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>187,804,752<\/td>\n<\/tr>\n
05 December 2006<\/td>828,540<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>188,633,292<\/td>\n<\/tr>\n
06 December 2006<\/td>185,150<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>188,818,442<\/td>\n<\/tr>\n
18 December 2006<\/td>1,238,648<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>190,057,090<\/td>\n<\/tr>\n
09 January 2007<\/td>299,324<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>190,356,414<\/td>\n<\/tr>\n
18 January 2007<\/td>706,654<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>191,063,068<\/td>\n<\/tr>\n
19 January 2007<\/td>216,008<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>191,279,076<\/td>\n<\/tr>\n
03 February 2007<\/td>623,333<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>191,902,409<\/td>\n<\/tr>\n
22 February 2007<\/td>222,179<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>192,124,588<\/td>\n<\/tr>\n
23 February 2007<\/td>135,467<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>192,260,055<\/td>\n<\/tr>\n
09 March 2007<\/td>277,725<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>192,537,780<\/td>\n<\/tr>\n
31 March 2007<\/td>864,340<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>193,402,120<\/td>\n<\/tr>\n
21 April 2007<\/td>1,016,778<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>194,418,898<\/td>\n<\/tr>\n
19 May 2007<\/td>518,417<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>194,937,315<\/td>\n<\/tr>\n
09 June 2007<\/td>1,139,901<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>196,077,216<\/td>\n<\/tr>\n
28 June 2007<\/td>1,018,323<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>197,095,539<\/td>\n<\/tr>\n
21 July 2007<\/td>842,430<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>197,937,969<\/td>\n<\/tr>\n
11 August 2007<\/td>1,247,972<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>199,185,941<\/td>\n<\/tr>\n
14 October 2007<\/td>339,441<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>199,525,382<\/td>\n<\/tr>\n
20 October 2007<\/td>864,034<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>200,389,416<\/td>\n<\/tr>\n
03 November 2007<\/td>509,161<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>200,898,577<\/td>\n<\/tr>\n
01 December 2007<\/td>208,599<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>201,107,176<\/td>\n<\/tr>\n
29 December 2007<\/td>339,439<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>201,446,615<\/td>\n<\/tr>\n
25 January 2008<\/td>30,858<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>201,477,473<\/td>\n<\/tr>\n
01 March 2008<\/td>3,120,084<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>204,597,557<\/td>\n<\/tr>\n
20 March 2008<\/td>2,518,834<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>207,116,391<\/td>\n<\/tr>\n
29 November 2010<\/td>1,035,581,955<\/td>1.00<\/td>Sub-division\/split of existing equity shares of Rs.5 each into five equity shares of Re.1 each<\/td>1,035,581,955<\/td>\n<\/tr>\n
03 August 2013<\/td>1,035,581,955<\/td>1.00<\/td>Bonus Issue
\n(in the ratio 1:1) <\/td>		2,071,163,910<\/td>\n<\/tr>\n
10 April 2015<\/td>334,956,764<\/td>1.00<\/td>Allotment pursuant to amalgamation of Ranbaxy Laboratories Limited
\n(in the ratio of 8:10)<\/td>		2,406,120,674<\/td>\n<\/tr>\n
29 April 2015<\/td>21,864<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,142,538<\/td>\n<\/tr>\n
29 April 2015<\/td>63,396<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,205,934<\/td>\n<\/tr>\n
29 April 2015<\/td>44,509<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,250,443<\/td>\n<\/tr>\n
29 April 2015<\/td>17,136<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,267,579<\/td>\n<\/tr>\n
29 April 2015<\/td>143,769<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,411,348<\/td>\n<\/tr>\n
29 April 2015<\/td>12,000<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,423,348<\/td>\n<\/tr>\n
23 July 2015<\/td>12,492<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,435,840<\/td>\n<\/tr>\n
23 July 2015<\/td>18,128<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,453,968<\/td>\n<\/tr>\n
23 July 2015<\/td>11,404<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,465,372<\/td>\n<\/tr>\n
23 July 2015<\/td>8,244<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,473,616<\/td>\n<\/tr>\n
23 July 2015<\/td>22,521<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,496,137<\/td>\n<\/tr>\n
31 October 2015<\/td>8,432<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,504,569<\/td>\n<\/tr>\n
31 October 2015<\/td>7,114<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,511,683<\/td>\n<\/tr>\n
31 October 2015<\/td>6,300<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,517,983<\/td>\n<\/tr>\n
31 October 2015<\/td>5,328<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,523,311<\/td>\n<\/tr>\n
31 October 2015<\/td>12,739<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,536,050<\/td>\n<\/tr>\n
31 October 2015<\/td>130,000<\/td>1.00<\/td>Shares allotted under ESOP<\/td>2,406,666,050<\/td>\n<\/tr>\n
12 February 2016<\/td>16,973<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,683,023<\/td>\n<\/tr>\n
12 February 2016<\/td>3,576<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,686,599<\/td>\n<\/tr>\n
12 February 2016<\/td>3,912<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,690,511<\/td>\n<\/tr>\n
12 February 2016<\/td>2,304<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,692,815<\/td>\n<\/tr>\n
12 February 2016<\/td>5,684<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,698,499<\/td>\n<\/tr>\n
12 February 2016<\/td>30,000<\/td>1.00<\/td>Shares allotted under ESOP<\/td>2,406,728,499<\/td>\n<\/tr>\n
02 May 2016<\/td>3,950<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,732,449<\/td>\n<\/tr>\n
02 May 2016<\/td>2,958<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,735,407<\/td>\n<\/tr>\n
02 May 2016<\/td>3,708<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,739,115<\/td>\n<\/tr>\n
02 May 2016<\/td>14,844<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,753,959<\/td>\n<\/tr>\n
21 October 2016<\/td>-7,500,000<\/td>1.00<\/td>Shares bought back destroyed<\/td>2,399,253,959<\/td>\n<\/tr>\n
22 November 2016<\/td>4,780<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,258,739<\/td>\n<\/tr>\n
22 November 2016<\/td>3,404<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,262,143<\/td>\n<\/tr>\n
22 November 2016<\/td>2,340<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,264,483<\/td>\n<\/tr>\n
22 November 2016<\/td>5,705<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,270,188<\/td>\n<\/tr>\n
14 February 2017<\/td>11,334<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,281,522<\/td>\n<\/tr>\n
14 February 2017<\/td>3,026<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,284,548<\/td>\n<\/tr>\n
14 February 2017<\/td>3,233<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,287,781<\/td>\n<\/tr>\n
14 February 2017<\/td>3,400<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,291,181<\/td>\n<\/tr>\n
26 May 2017<\/td>1,560<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,292,741<\/td>\n<\/tr>\n
26 May 2017<\/td>360<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,293,101<\/td>\n<\/tr>\n
26 May 2017<\/td>1,080<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,294,181<\/td>\n<\/tr>\n
26 May 2017<\/td>12,000<\/td>1.00<\/td>Shares allotted under ESOP<\/td>2,399,306,181<\/td>\n<\/tr>\n
11 August 2017<\/td>244<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,306,425<\/td>\n<\/tr>\n
11 August 2017<\/td>180<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,306,605<\/td>\n<\/tr>\n
11 August 2017<\/td>375<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,306,980<\/td>\n<\/tr>\n
26 September 2017<\/td>1,106<\/td>1.00<\/td>Shares allotted under ESOP<\/td>2,399,308,086<\/td>\n<\/tr>\n
14 November 2017<\/td>1,260<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,309,346<\/td>\n<\/tr>\n
14 February 2018<\/td>12,652<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,321,998<\/td>\n<\/tr>\n
14 February 2018<\/td>792<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,322,790<\/td>\n<\/tr>\n
14 February 2018<\/td>390<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,323,180<\/td>\n<\/tr>\n
24 May 2018<\/td>720<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,323,900<\/td>\n<\/tr>\n
24 May 2018<\/td>594<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,324,494<\/td>\n<\/tr>\n
13 August 2018<\/td>180<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,324,674<\/td>\n<\/tr>\n
12 November 2018<\/td>2,160<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,326,834<\/td>\n<\/tr>\n
12 November 2018<\/td>1,440<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,328,274<\/td>\n<\/tr>\n
11 February 2019<\/td>6,696<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,334,970<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n[\/et_pb_code][et_pb_text _builder_version=”4.7.4″ _module_preset=”default”]<\/p>\n

Note :<\/strong>
Shares allotted under ESOS \u2013 Allotment under Sun Employee Stock Option Scheme -2015 to employees<\/span>
Shares allotted under ESOP – Allotment under Sun Employee Stock Option Plan -2015 to Sun Pharma ESOP Trust for allocation to employees<\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.7.4″ _module_preset=”default” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on” da_disable_devices=”off|off|off”][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.7.4″ _module_preset=”default” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on” da_disable_devices=”off|off|off”][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.Capital Evolution\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Date of Allotment<\/th>No. of equity shares issued<\/th>Face Value (Rs.)<\/th>Type of Issue<\/th>Cumulative capital
\n(No. of equity shares)<\/th>\n<\/tr>\n<\/thead>\n
01 March 1993<\/td>200,000<\/td>10.00<\/td>Conversion of Partnership Firm<\/td>200,000<\/td>\n<\/tr>\n
30 March 1993<\/td>700,000<\/td>10.00<\/td>Cash<\/td>900,000<\/td>\n<\/tr>\n
18 September 1993<\/td>5,100,000<\/td>10.00<\/td>Cash<\/td>6,000,000<\/td>\n<\/tr>\n
10 November 1993<\/td>1,000,000<\/td>10.00<\/td>Rights Issue<\/td>7,000,000<\/td>\n<\/tr>\n
08 January 1994<\/td>185,000<\/td>10.00<\/td>Cash<\/td>7,185,000<\/td>\n<\/tr>\n
01 June 1994<\/td>3,592,500<\/td>10.00<\/td>Bonus Issue
\n(in the ratio 1:2)<\/td>		10,777,500<\/td>\n<\/tr>\n
09 August 1994<\/td>323,400<\/td>10.00<\/td>Rights Issue<\/td>11,100,900<\/td>\n<\/tr>\n
08 December 1994<\/td>3,700,300<\/td>10.00<\/td>Public Issue<\/td>14,801,200<\/td>\n<\/tr>\n
07 February 1998<\/td>413,633<\/td>10.00<\/td>Allotment pursuant to amalgamation of Tamilnadu Dadha Pharmaceuticals Ltd.
\n(in the ratio of 1:4)<\/td>		15,214,833<\/td>\n<\/tr>\n
25 March 1999<\/td>208,000<\/td>10.00<\/td>Allotment pursuant to amalgamation of Milmet Laboratories Private Limited
\n(in the ratio of 4:5)<\/td>		15,422,833<\/td>\n<\/tr>\n
01 April 2000<\/td>30,844,466<\/td>10.00<\/td>Bonus Issue
\n(in the ratio 2:1)<\/td>		46,267,299<\/td>\n<\/tr>\n
06 June 2000<\/td>477,581<\/td>10.00<\/td>Allotment pursuant to amalgamation of Gujarat Lyka Organics Limited
\n(In the ratio of 1:21.33)<\/td>		46,744,880<\/td>\n<\/tr>\n
16 January 2001<\/td>11,438<\/td>10.00<\/td>Allotment pursuant to amalgamation of Sun Pharmaceutical Exports Limited
\n(in the ratio of 4:5)<\/td>		46,756,318<\/td>\n<\/tr>\n
16 January 2001<\/td>200<\/td>10.00<\/td>Bonus (kept in abeyance)<\/td>46,756,518<\/td>\n<\/tr>\n
22 March 2001<\/td>-500<\/td>10.00<\/td>Forfeited by the Board of Directors at their Board Meeting held on 22.03.2001<\/td>46,756,018<\/td>\n<\/tr>\n
30 March 2002<\/td>18,519<\/td>10.00<\/td>Allotment pursuant to amalgamation of Pradeep Drug Company Limited
\n(in the ratio of 1:500)<\/td>		46,774,537<\/td>\n<\/tr>\n
28 August 2002<\/td>19,771<\/td>10.00<\/td>Allotment pursuant to amalgamation of M. J. Pharmaceuticals Limited
\n(in the ratio of 1:210)<\/td>		46,794,308<\/td>\n<\/tr>\n
21 January 2003<\/td>93,588,616<\/td>5.00<\/td>Sub-division\/split of existing equity shares of Rs.10 each into two equity shares of Rs.5 each<\/td>93,588,616<\/td>\n<\/tr>\n
15 March 2003<\/td>-209,000<\/td>5.00<\/td>Shares bought back destroyed<\/td>93,379,616<\/td>\n<\/tr>\n
28 March 2003<\/td>-156,838<\/td>5.00<\/td>Shares bought back destroyed<\/td>93,222,778<\/td>\n<\/tr>\n
16 April 2003<\/td>-174,300<\/td>5.00<\/td>Shares bought back destroyed<\/td>93,048,478<\/td>\n<\/tr>\n
08 May 2003<\/td>-262,732<\/td>5.00<\/td>Shares bought back destroyed<\/td>92,785,746<\/td>\n<\/tr>\n
23 May 2003<\/td>-30,068<\/td>5.00<\/td>Shares bought back destroyed<\/td>92,755,678<\/td>\n<\/tr>\n
08 June 2004<\/td>92,755,678<\/td>5.00<\/td>Bonus Issue
\n(in the ratio 1:1) <\/td>		185,511,356<\/td>\n<\/tr>\n
18 August 2005<\/td>4,274<\/td>5.00<\/td>Allotment pursuant to amalgamation of Phlox Pharmaceuticals Limited
\n(in the ratio of 1:790)<\/td>		185,515,630<\/td>\n<\/tr>\n
31 March 2006<\/td>216,007<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>185,731,637<\/td>\n<\/tr>\n
22 April 2006<\/td>154,291<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>185,885,928<\/td>\n<\/tr>\n
16 May 2006<\/td>61,716<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>185,947,644<\/td>\n<\/tr>\n
07 June 2006<\/td>58,445<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>186,006,089<\/td>\n<\/tr>\n
14 June 2006<\/td>61,716<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>186,067,805<\/td>\n<\/tr>\n
04 September 2006<\/td>30,858<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>186,098,663<\/td>\n<\/tr>\n
13 September 2006<\/td>98,746<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>186,197,409<\/td>\n<\/tr>\n
16 September 2006<\/td>462,875<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>186,660,284<\/td>\n<\/tr>\n
09 October 2006<\/td>306,668<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>186,966,952<\/td>\n<\/tr>\n
11 October 2006<\/td>61,716<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>187,028,668<\/td>\n<\/tr>\n
06 November 2006<\/td>262,293<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>187,290,961<\/td>\n<\/tr>\n
18 November 2006<\/td>50,916<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>187,341,877<\/td>\n<\/tr>\n
20 November 2006<\/td>462,875<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>187,804,752<\/td>\n<\/tr>\n
05 December 2006<\/td>828,540<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>188,633,292<\/td>\n<\/tr>\n
06 December 2006<\/td>185,150<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>188,818,442<\/td>\n<\/tr>\n
18 December 2006<\/td>1,238,648<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>190,057,090<\/td>\n<\/tr>\n
09 January 2007<\/td>299,324<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>190,356,414<\/td>\n<\/tr>\n
18 January 2007<\/td>706,654<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>191,063,068<\/td>\n<\/tr>\n
19 January 2007<\/td>216,008<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>191,279,076<\/td>\n<\/tr>\n
03 February 2007<\/td>623,333<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>191,902,409<\/td>\n<\/tr>\n
22 February 2007<\/td>222,179<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>192,124,588<\/td>\n<\/tr>\n
23 February 2007<\/td>135,467<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>192,260,055<\/td>\n<\/tr>\n
09 March 2007<\/td>277,725<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>192,537,780<\/td>\n<\/tr>\n
31 March 2007<\/td>864,340<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>193,402,120<\/td>\n<\/tr>\n
21 April 2007<\/td>1,016,778<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>194,418,898<\/td>\n<\/tr>\n
19 May 2007<\/td>518,417<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>194,937,315<\/td>\n<\/tr>\n
09 June 2007<\/td>1,139,901<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>196,077,216<\/td>\n<\/tr>\n
28 June 2007<\/td>1,018,323<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>197,095,539<\/td>\n<\/tr>\n
21 July 2007<\/td>842,430<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>197,937,969<\/td>\n<\/tr>\n
11 August 2007<\/td>1,247,972<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>199,185,941<\/td>\n<\/tr>\n
14 October 2007<\/td>339,441<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>199,525,382<\/td>\n<\/tr>\n
20 October 2007<\/td>864,034<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>200,389,416<\/td>\n<\/tr>\n
03 November 2007<\/td>509,161<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>200,898,577<\/td>\n<\/tr>\n
01 December 2007<\/td>208,599<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>201,107,176<\/td>\n<\/tr>\n
29 December 2007<\/td>339,439<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>201,446,615<\/td>\n<\/tr>\n
25 January 2008<\/td>30,858<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>201,477,473<\/td>\n<\/tr>\n
01 March 2008<\/td>3,120,084<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>204,597,557<\/td>\n<\/tr>\n
20 March 2008<\/td>2,518,834<\/td>5.00<\/td>Allotment against conversion of FCCBs<\/td>207,116,391<\/td>\n<\/tr>\n
29 November 2010<\/td>1,035,581,955<\/td>1.00<\/td>Sub-division\/split of existing equity shares of Rs.5 each into five equity shares of Re.1 each<\/td>1,035,581,955<\/td>\n<\/tr>\n
03 August 2013<\/td>1,035,581,955<\/td>1.00<\/td>Bonus Issue
\n(in the ratio 1:1) <\/td>		2,071,163,910<\/td>\n<\/tr>\n
10 April 2015<\/td>334,956,764<\/td>1.00<\/td>Allotment pursuant to amalgamation of Ranbaxy Laboratories Limited
\n(in the ratio of 8:10)<\/td>		2,406,120,674<\/td>\n<\/tr>\n
29 April 2015<\/td>21,864<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,142,538<\/td>\n<\/tr>\n
29 April 2015<\/td>63,396<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,205,934<\/td>\n<\/tr>\n
29 April 2015<\/td>44,509<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,250,443<\/td>\n<\/tr>\n
29 April 2015<\/td>17,136<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,267,579<\/td>\n<\/tr>\n
29 April 2015<\/td>143,769<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,411,348<\/td>\n<\/tr>\n
29 April 2015<\/td>12,000<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,423,348<\/td>\n<\/tr>\n
23 July 2015<\/td>12,492<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,435,840<\/td>\n<\/tr>\n
23 July 2015<\/td>18,128<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,453,968<\/td>\n<\/tr>\n
23 July 2015<\/td>11,404<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,465,372<\/td>\n<\/tr>\n
23 July 2015<\/td>8,244<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,473,616<\/td>\n<\/tr>\n
23 July 2015<\/td>22,521<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,496,137<\/td>\n<\/tr>\n
31 October 2015<\/td>8,432<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,504,569<\/td>\n<\/tr>\n
31 October 2015<\/td>7,114<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,511,683<\/td>\n<\/tr>\n
31 October 2015<\/td>6,300<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,517,983<\/td>\n<\/tr>\n
31 October 2015<\/td>5,328<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,523,311<\/td>\n<\/tr>\n
31 October 2015<\/td>12,739<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,536,050<\/td>\n<\/tr>\n
31 October 2015<\/td>130,000<\/td>1.00<\/td>Shares allotted under ESOP<\/td>2,406,666,050<\/td>\n<\/tr>\n
12 February 2016<\/td>16,973<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,683,023<\/td>\n<\/tr>\n
12 February 2016<\/td>3,576<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,686,599<\/td>\n<\/tr>\n
12 February 2016<\/td>3,912<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,690,511<\/td>\n<\/tr>\n
12 February 2016<\/td>2,304<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,692,815<\/td>\n<\/tr>\n
12 February 2016<\/td>5,684<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,698,499<\/td>\n<\/tr>\n
12 February 2016<\/td>30,000<\/td>1.00<\/td>Shares allotted under ESOP<\/td>2,406,728,499<\/td>\n<\/tr>\n
02 May 2016<\/td>3,950<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,732,449<\/td>\n<\/tr>\n
02 May 2016<\/td>2,958<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,735,407<\/td>\n<\/tr>\n
02 May 2016<\/td>3,708<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,739,115<\/td>\n<\/tr>\n
02 May 2016<\/td>14,844<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,406,753,959<\/td>\n<\/tr>\n
21 October 2016<\/td>-7,500,000<\/td>1.00<\/td>Shares bought back destroyed<\/td>2,399,253,959<\/td>\n<\/tr>\n
22 November 2016<\/td>4,780<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,258,739<\/td>\n<\/tr>\n
22 November 2016<\/td>3,404<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,262,143<\/td>\n<\/tr>\n
22 November 2016<\/td>2,340<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,264,483<\/td>\n<\/tr>\n
22 November 2016<\/td>5,705<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,270,188<\/td>\n<\/tr>\n
14 February 2017<\/td>11,334<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,281,522<\/td>\n<\/tr>\n
14 February 2017<\/td>3,026<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,284,548<\/td>\n<\/tr>\n
14 February 2017<\/td>3,233<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,287,781<\/td>\n<\/tr>\n
14 February 2017<\/td>3,400<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,291,181<\/td>\n<\/tr>\n
26 May 2017<\/td>1,560<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,292,741<\/td>\n<\/tr>\n
26 May 2017<\/td>360<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,293,101<\/td>\n<\/tr>\n
26 May 2017<\/td>1,080<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,294,181<\/td>\n<\/tr>\n
26 May 2017<\/td>12,000<\/td>1.00<\/td>Shares allotted under ESOP<\/td>2,399,306,181<\/td>\n<\/tr>\n
11 August 2017<\/td>244<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,306,425<\/td>\n<\/tr>\n
11 August 2017<\/td>180<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,306,605<\/td>\n<\/tr>\n
11 August 2017<\/td>375<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,306,980<\/td>\n<\/tr>\n
26 September 2017<\/td>1,106<\/td>1.00<\/td>Shares allotted under ESOP<\/td>2,399,308,086<\/td>\n<\/tr>\n
14 November 2017<\/td>1,260<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,309,346<\/td>\n<\/tr>\n
14 February 2018<\/td>12,652<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,321,998<\/td>\n<\/tr>\n
14 February 2018<\/td>792<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,322,790<\/td>\n<\/tr>\n
14 February 2018<\/td>390<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,323,180<\/td>\n<\/tr>\n
24 May 2018<\/td>720<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,323,900<\/td>\n<\/tr>\n
24 May 2018<\/td>594<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,324,494<\/td>\n<\/tr>\n
13 August 2018<\/td>180<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,324,674<\/td>\n<\/tr>\n
12 November 2018<\/td>2,160<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,326,834<\/td>\n<\/tr>\n
12 November 2018<\/td>1,440<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,328,274<\/td>\n<\/tr>\n
11 February 2019<\/td>6,696<\/td>1.00<\/td>Shares allotted under ESOS<\/td>2,399,334,970<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nNote : Shares allotted under ESOS \u2013 Allotment under Sun Employee Stock Option Scheme -2015 to employees Shares allotted under ESOP – Allotment […]<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"class_list":["post-16404","page","type-page","status-publish","hentry"],"yoast_head":"\nCapital Evolution - Sun Pharmaceutical<\/title>\n<meta name=\"description\" content=\"At Sun, we remain committed to creating long term value for our shareholders Dividend History. In line with this philosophy, we will continue to focus on performance and producing consistent returns.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dev.sunpharma.com\/he\/capital-evolution\/\" \/>\n<meta property=\"og:locale\" content=\"he_IL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Capital Evolution - Sun Pharmaceutical\" \/>\n<meta property=\"og:description\" content=\"At Sun, we remain committed to creating long term value for our shareholders Dividend History. In line with this philosophy, we will continue to focus on performance and producing consistent returns.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.sunpharma.com\/he\/capital-evolution\/\" \/>\n<meta property=\"og:site_name\" content=\"Sun Pharmaceutical Industries Ltd.\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-09T03:29:43+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u05d3\u05e7\u05d41\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/capital-evolution\\\/\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/capital-evolution\\\/\",\"name\":\"Capital Evolution - Sun Pharmaceutical\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#website\"},\"datePublished\":\"2024-12-04T16:31:00+00:00\",\"dateModified\":\"2024-12-09T03:29:43+00:00\",\"description\":\"At Sun, we remain committed to creating long term value for our shareholders Dividend History. In line with this philosophy, we will continue to focus on performance and producing consistent returns.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/capital-evolution\\\/#breadcrumb\"},\"inLanguage\":\"he-IL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/dev.sunpharma.com\\\/capital-evolution\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/capital-evolution\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/dev.sunpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Capital Evolution\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dev.sunpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/dev.sunpharma.com\\\/\",\"name\":\"Sun Pharmaceutical Industries Ltd.\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dev.sunpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"he-IL\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Capital Evolution - Sun Pharmaceutical","description":"At Sun, we remain committed to creating long term value for our shareholders Dividend History. In line with this philosophy, we will continue to focus on performance and producing consistent returns.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dev.sunpharma.com\/he\/capital-evolution\/","og_locale":"he_IL","og_type":"article","og_title":"Capital Evolution - Sun Pharmaceutical","og_description":"At Sun, we remain committed to creating long term value for our shareholders Dividend History. In line with this philosophy, we will continue to focus on performance and producing consistent returns.","og_url":"https:\/\/dev.sunpharma.com\/he\/capital-evolution\/","og_site_name":"Sun Pharmaceutical Industries Ltd.","article_modified_time":"2024-12-09T03:29:43+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"\u05d3\u05e7\u05d41"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dev.sunpharma.com\/capital-evolution\/","url":"https:\/\/dev.sunpharma.com\/capital-evolution\/","name":"Capital Evolution - Sun Pharmaceutical","isPartOf":{"@id":"https:\/\/dev.sunpharma.com\/#website"},"datePublished":"2024-12-04T16:31:00+00:00","dateModified":"2024-12-09T03:29:43+00:00","description":"At Sun, we remain committed to creating long term value for our shareholders Dividend History. In line with this philosophy, we will continue to focus on performance and producing consistent returns.","breadcrumb":{"@id":"https:\/\/dev.sunpharma.com\/capital-evolution\/#breadcrumb"},"inLanguage":"he-IL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.sunpharma.com\/capital-evolution\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dev.sunpharma.com\/capital-evolution\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dev.sunpharma.com\/"},{"@type":"ListItem","position":2,"name":"Capital Evolution"}]},{"@type":"WebSite","@id":"https:\/\/dev.sunpharma.com\/#website","url":"https:\/\/dev.sunpharma.com\/","name":"Sun Pharmaceutical Industries Ltd.","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.sunpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"he-IL"}]}},"_links":{"self":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/16404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/comments?post=16404"}],"version-history":[{"count":4,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/16404\/revisions"}],"predecessor-version":[{"id":16416,"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/pages\/16404\/revisions\/16416"}],"wp:attachment":[{"href":"https:\/\/dev.sunpharma.com\/he\/wp-json\/wp\/v2\/media?parent=16404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}